Skip to main content

Analysts Conflicted on These Healthcare Names: CareDx (CDNA) and DaVita (DVA)

Tipranks - Tipranks - Wed Feb 4, 8:50AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CareDx (CDNA – Research Report) and DaVita (DVA – Research Report).

Claim 50% Off TipRanks Premium

CareDx (CDNA)

Craig-Hallum analyst William Bonello maintained a Hold rating on CareDx today. The company’s shares closed last Tuesday at $20.90.

According to TipRanks.com, Bonello is a 5-star analyst with an average return of 38.6% and a 68.5% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, SOPHiA GENETICS, and Guardant Health. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for CareDx with a $18.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

DaVita (DVA)

Bank of America Securities analyst Kevin Fischbeck maintained a Sell rating on DaVita today. The company’s shares closed last Tuesday at $135.50.

According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of 3.2% and a 59.9% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., AMN Healthcare Services, and Tenet Healthcare. ;'>

DaVita has an analyst consensus of Moderate Sell, with a price target consensus of $158.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).